Onco-Carbide en es it fr

Onco-Carbide Brand names, Onco-Carbide Analogs

Onco-Carbide Brand Names Mixture

  • No information avaliable

Onco-Carbide Chemical_Formula


Onco-Carbide RX_link


Onco-Carbide fda sheet

Onco-Carbide FDA

Onco-Carbide msds (material safety sheet)

Onco-Carbide MSDS

Onco-Carbide Synthesis Reference

No information avaliable

Onco-Carbide Molecular Weight

76.0547 g/mol

Onco-Carbide Melting Point

142-146 oC

Onco-Carbide H2O Solubility

1E+006 mg/L

Onco-Carbide State


Onco-Carbide LogP


Onco-Carbide Dosage Forms


Onco-Carbide Indication

For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.

Onco-Carbide Pharmacology

Hydroxyurea has dose-dependent synergistic activity with cisplatin in vitro. In vivo Hydroxyurea showed activity in combination with cisplatin against the LX-1 and CALU-6 human lung xenografts, but minimal activity was seen with the NCI-H460 or NCI-H520 xenografts. Hydroxyurea was synergistic with cisplatin in the Lewis lung murine xenograft. Sequential exposure to Hydroxyurea 4 hours before cisplatin produced the greatest interaction.

Onco-Carbide Absorption

Well absorbed from the gastrointestinal tract.

Onco-Carbide side effects and Toxicity

Oral, mouse: LD50 = 7330 mg/kg; Oral, rat: LD50 = 5760 mg/kg

Onco-Carbide Patient Information

HYDREA is a medication that must be handled with care. People who are not taking HYDREA should not be exposed to it. If the powder from the capsule is spilled, it should be wiped up immediately with a damp disposable towel and discarded in a closed container, such as a plastic bag. The medication should be kept away from children and pets.

Onco-Carbide Organisms Affected

Humans and other mammals